{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-017551","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2023-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.900480+00:00","generated_at":"2026-06-20T07:20:58.563475+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Ginkgo files Zymergen Q3 2022 financials; net loss $75.7M on $2.3M revenue","bullets":["Zymergen Q3 2022: revenue $2.3M, net loss $75.7M, operating loss $75.3M.","Nine-month 2022: revenue $9.7M, net loss $264.3M, operating loss $245.1M.","Cash $153.4M at Sep 30, 2022, down from $386.1M at Dec 31, 2021.","Goodwill impairment charge of $40.6M recorded during 2022.","Going-concern doubt that existed at June 30, 2022 alleviated by Oct 19, 2022 merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-017551","json":"https://secwatch.observer/filing/0001193125-23-017551.json","markdown":"https://secwatch.observer/filing/0001193125-23-017551.md","text":"https://secwatch.observer/filing/0001193125-23-017551.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000119312523017551/0001193125-23-017551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000119312523017551/d443681d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T07:20:58.563475+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}